In a groundbreaking collaboration, Jiangsu Aidea Pharma and Nanjing PharmaBlock are teaming up with Fidson Healthcare in Nigeria to establish a cutting-edge $100 million antiretroviral drug plant. Meanwhile, in Zanzibar, Africa Bio Chem has inked a deal for vaccine and drug production, and Zambia is set to house a state-of-the-art cholera vaccine facility developed by Jijia International Medical Technology. These strategic partnerships signal a shift towards bolstering Africa’s pharmaceutical sector through local manufacturing and expertise. From Kenya to Rwanda, the continent is witnessing a surge in investments and workforce development to reduce dependence on foreign pharma supply chains and enhance self-sufficiency. The recent success story of Revital Healthcare in Kenya, which now produces WHO-prequalified auto-disable syringes for vaccinations, exemplifies the positive impact of local efforts in strengthening Africa’s healthcare infrastructure. With over 300 million units manufactured in 2023 alone, Revital is playing a pivotal role in supplying essential medical devices to more than 30 African nations, marking a significant step towards achieving a more resilient and self-reliant pharmaceutical landscape in the region.
Read more from independent.co.ug